IRIS
POLONI, Antonella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.571
EU - Europa 5.948
AS - Asia 5.167
SA - Sud America 1.400
Continente sconosciuto - Info sul continente non disponibili 554
AF - Africa 316
OC - Oceania 14
AN - Antartide 1
Totale 24.971
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.363
SG - Singapore 1.583
IT - Italia 1.285
VN - Vietnam 1.182
BR - Brasile 1.098
RU - Federazione Russa 1.004
CN - Cina 837
UA - Ucraina 789
DE - Germania 505
IE - Irlanda 482
SE - Svezia 439
HK - Hong Kong 418
FR - Francia 342
TR - Turchia 335
FI - Finlandia 302
DK - Danimarca 290
GB - Regno Unito 223
KR - Corea 167
IN - India 152
CI - Costa d'Avorio 115
BD - Bangladesh 106
AR - Argentina 100
CA - Canada 98
MA - Marocco 76
MX - Messico 71
NL - Olanda 71
IQ - Iraq 63
JP - Giappone 54
PL - Polonia 49
CO - Colombia 47
ZA - Sudafrica 45
AT - Austria 41
EC - Ecuador 41
ID - Indonesia 39
VE - Venezuela 37
PK - Pakistan 31
UZ - Uzbekistan 31
ES - Italia 27
BE - Belgio 25
PY - Paraguay 24
TN - Tunisia 23
CL - Cile 21
EU - Europa 19
AE - Emirati Arabi Uniti 18
DZ - Algeria 16
PE - Perù 16
PH - Filippine 16
MY - Malesia 15
HU - Ungheria 14
AU - Australia 13
AZ - Azerbaigian 12
EG - Egitto 12
KE - Kenya 12
SA - Arabia Saudita 12
JO - Giordania 11
IL - Israele 9
UY - Uruguay 9
CH - Svizzera 8
BG - Bulgaria 7
CR - Costa Rica 7
IR - Iran 7
KZ - Kazakistan 7
TW - Taiwan 7
BH - Bahrain 6
CZ - Repubblica Ceca 6
DO - Repubblica Dominicana 6
LB - Libano 6
LT - Lituania 6
TH - Thailandia 6
AL - Albania 5
BO - Bolivia 5
KG - Kirghizistan 5
NP - Nepal 5
SN - Senegal 5
HN - Honduras 4
KW - Kuwait 4
MN - Mongolia 4
OM - Oman 4
PS - Palestinian Territory 4
RO - Romania 4
BZ - Belize 3
GA - Gabon 3
GT - Guatemala 3
HR - Croazia 3
MD - Moldavia 3
PR - Porto Rico 3
PT - Portogallo 3
DM - Dominica 2
EE - Estonia 2
ET - Etiopia 2
GY - Guiana 2
JM - Giamaica 2
MQ - Martinica 2
MT - Malta 2
NI - Nicaragua 2
QA - Qatar 2
RS - Serbia 2
SY - Repubblica araba siriana 2
AI - Anguilla 1
AQ - Antartide 1
Totale 24.408
Salva come PNG Salva come JPEG
Città #
Ashburn 1.542
Singapore 927
Jacksonville 824
Chandler 752
Fairfield 620
Dallas 597
Council Bluffs 574
Dublin 482
San Jose 477
Boardman 471
Hong Kong 399
Ho Chi Minh City 395
New York 340
Des Moines 337
Wilmington 332
Hanoi 272
Houston 255
Seattle 238
The Dalles 232
Los Angeles 213
Woodbridge 209
Beijing 200
Lauterbourg 195
Princeton 184
Lawrence 182
San Mateo 176
Moscow 167
Cambridge 147
Ann Arbor 129
Milan 129
Hefei 126
Helsinki 120
Chicago 116
Abidjan 115
Centro 112
São Paulo 83
Ancona 81
San Diego 78
Buffalo 75
Munich 74
Redmond 74
Orem 67
Rome 65
Turin 65
Da Nang 57
Haiphong 56
Santa Clara 53
London 46
Marche 46
Salt Lake City 43
Pune 41
Denver 40
Shanghai 40
Guangzhou 37
Frankfurt am Main 34
Phoenix 33
Porto 33
Tokyo 33
Warsaw 33
Nuremberg 32
Montreal 31
Amsterdam 30
Chennai 28
Norwalk 27
Pianella 27
Stockholm 27
Tashkent 27
Turku 27
Atlanta 26
Rio de Janeiro 26
Washington 26
Brooklyn 25
Johannesburg 25
Miano 23
Vienna 23
Brussels 22
Naples 22
Baghdad 21
Belo Horizonte 20
Mexico City 20
Poplar 20
Biên Hòa 19
Boston 19
Columbus 19
Elk Grove Village 19
Brasília 18
Medellín 18
Mumbai 18
Toronto 18
Curitiba 17
Hải Dương 17
San Francisco 16
Tampa 16
Hangzhou 15
Can Tho 14
Falconara Marittima 14
Lahore 14
Manchester 14
Paris 14
Philadelphia 14
Totale 14.741
Salva come PNG Salva come JPEG
Nome #
The Time Has Come for Targeted Therapies for AML: Lights and Shadows 382
Algoritmi diagnostico-terapeutici in Ematologia 319
Human white adipocytes convert into “rainbow” adipocytes in vitro 267
Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations 252
A novel method to evaluate prethawing viability of cryopreserved CD34+ hematopoietic stem cells for autologous transplantation. 225
Human de-differentiated adipocytes show similar properties to bone marrow derived mesenchymal stem cells 221
Feasibility and Outcome of a Phase II Study of Intensive Induction Chemotherapy in 91 Elderly Patients with AML Evaluated Using a Simplified Multidimensional Geriatric Assessment 212
Apoptotic mechanism activated by blue light and cisplatinum in cutaneous squamous cell carcinoma cells 208
Serum Inflamma-miR Signature: A Biomarker of Myelodysplastic Syndrome? 206
Immunomodulatory Effects of Tyrosine Kinase Inhibitor In Vitro and In Vivo Study 193
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. 192
Low-dose Gemtuzumab-Ozogamicin as post-consolidation therapy in elderly patients with acute myeloid leukaemia: a pilot study. 189
Adipocytes properties and crosstalk with immune system in obesity-related inflammation. 179
Conditioning regimen with beam plus amifostine for outpatient autologous stem cell tansplantation: feasibility and outcome in 97 lymphoma patients. 177
Glial-like differentiation potential of human mature adipocytes 171
In vitro comparison of different TKI activity in T-Cell populations: selective sparing of Treg by Nilotinib. 168
Aging- and Senescence-associated Changes of Mesenchymal Stromal Cells in Myelodysplastic Syndromes 168
Nilotinib Treatment of Patients Affected by Chronic Graft-versus-Host Disease Reduces Collagen Production and Skin Fibrosis by Downmodulating the TGF-β and p-SMAD Pathway 167
Bone marrow adipose tissue is a unique adipose subtype with distinct roles in glucose homeostasis 167
Gene expression profile of cytokines in patients with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with reduced conditioning. 165
Mobilization-Driven Postconsolidation Therapy in Elderly Patients with Acute Myeloid Leukemia: Feasibility and Efficacy of Autologous Stem Cell Transplantation versus Low-Dose Gemtuzumab Ozogamicin 164
Uncommon Presentation of Sarcoidosis with Severe Thrombocytopenia and Hemorrhagic Diathesis 161
A Combination of Lenalidomide and Rituximab (ReRi) As Salvage Therapy in Elderly Patients Affected By Diffuse Large B Cells (DLBCL) Lymphoma Relapsed and Refractory 161
Efficacy and feasibility of high-dose cytarabine plus idarubicin and amifostine as induction schedule: a prospective observational study of 100 AML elderly patients 160
Acute promyelocyte leukemia arose from CALR 1 mutated post essential thrombocythemia- myelofibrosis with splanchnic vein thrombosis: A case report 157
Azacitidine Treatment in High Risk Myelodysplastic Patients in Complete Haematological Remission Reverts Mesenchymal Stem Cells to a Normal Phenotype 156
Shaping the Future of Myeloproliferative Neoplasm Therapy: Immune-Based Strategies and Targeted Innovations 155
A real life survey on erytropoietin alpha treatment in a cohort of 1049 low risk MDS patients: an italian MDS registry study 155
Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study 154
Human bone marrow adipocytes maintain the survival and differentiation of hematopoietic stem cells 154
A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation. 154
Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease 152
Bone marrow adipocytes support haematopoietic stem cell survival 152
A 50 Hz magnetic field influences the viability of breast cancer cells 96 h after exposure 151
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. 151
Low FasL levels promote proliferation of human bone marrow-derived mesenchymal stem cells, higher levels inhibit their differentiation into adipocytes. 150
The exosomal surface phenotype and inflamma-miR cargo correlate with MDS diagnosis 150
Prognostic role of immunohistochemical analysis of 5 mc in myelodysplastic syndromes. 147
Biosafety evidence for human dedifferentiated adipocytes 147
Bone Marrow "Yellow" and "Red" Adipocytes: Good or Bad Cells? 147
Gemtuzumab-Ozogamicin as Post-Consolidation Therapy In Elderly Patients with Acute Myeloid Leukemia: a Pilot Study 145
A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patients. 144
A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia 144
High predictive value of the revised international prognostic scoring system (IPSS-R): an external analysis of 646 patients from a multiregional italian MDS registry 143
Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cell autotransplant: a retrospective study 143
The Exaggerated Collagen Expression in Gvhd-Fibroblasts Is Effectively Inhibited By Therapeutic Concentration of Nilotinib 143
Cytokine expression profile of selected cell populations from patients with chronic graft-versus-host disease after allogeneic bone marrow transplantation wih reduced conditioning. 141
Human Mesenchymal Stem Cells from chorionic villi and amniotic fluid are not susceptible to transformation after extensive in vitro expansion 141
Hematologic reconstitution after PBPC autotransplantation:comparison between programmed-rate freezing and uncontrolled freezing at –80° 140
LATE EFFECTS IN Hodgkin's POPULATION Treated BETWEEN 1980-2005 IN A SINGLE INSTITUTION 139
Plasticity of human dedifferentiated adipocytes toward endothelial cells 138
Human AB serum for generation of mesenchymal stem cells from human chorionic villi: comparison with other source and other media including platelet lysate 138
A rare case of aCML associated with CNS involvement and with aggressive clinical course 138
Preventive Effects of Cardotoxicities By Liposomal Anthracyclines non Pegilated in 95 Perspective Patients Affected By Lymphoma and Monitored By Biomarkers and Ecocardiography 136
Tailored Therapy in an Unselected Population of 91 Elderly Patients with DLBCL Prospectively Evaluated Using a Simplified CGA. 136
MiR-422a promotes adipogenesis via MeCP2 downregulation in human bone marrow mesenchymal stem cells 135
Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications 132
Targeting the immune system in MDS and MPN: Understanding the immunome and response to immunotherapy - Part 2 131
LA POSITIVITÀ DEL WT1 POST-INDUZIONE È UN IMPORTANTE FATTORE PROGNOSTICO PREDITTIVO DI RECIDIVA PRECOCE IN UNA CASISTICA DI 80 PAZIENTI AFFETTI DA LEUCEMIA ACUTA MIELOIDE 131
Screening of psychological distress in oncology and hematology department at Ospedali Riuniti Ancona 131
A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell trasplantation 130
Iron overload alters the energy metabolism in patients with myelodysplastic syndromes: results from the multicenter FISM BIOFER study 130
NOVELTIES ON MULTIPLE MYELOMA FROM THE MAIN 2024 HEMATOLOGY CONFERENCES 129
Overexpression of CDKN2B (p15INK4B) and altered global DNA methylation status in mesenchymal stem cells of high-risk myelodysplastic syndromes 129
Hematologic reconstitution after PBPC autotransplantation: comparison between programmed-rate freezing and uncontrolled-rate freezing at -80 degrees C 128
Interaction between human mature adipocytes and lymphocytes induces T-cell proliferation 126
Molecular and functional characterization of human bone marrow adipocytes 126
History and scientific production of clinica medica and clinica ematologica in ancona 126
Novel Translational Read-Through–Inducing Drugs as A Therapeutic Option for Shwachman-Diamond Syndrome 126
Bone Marrow Adipose Tissue 124
Patients with chronic extensive GvHD produce high levels of stimulatory auto-antibodies to the PDGF receptor: a new pathophysiological pathway of the disease progression 124
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD 124
Efficacy and safety of eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: interim analysis of a prospective, randomized, single-blind, placebo-controlled trial (EQoL-MDS) 122
Identification of different adypocytes populations within human marrow microenvironment 122
Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study 121
Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality 119
Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders. 118
ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems 118
Selection of CD271(+) cells and human AB serum allows a large expansion of mesenchymal stromal cells from human bone marrow 117
Characterization and expansion of mesenchymal progenitor cells from first-trimester chorionic villi of human placenta. 116
mTOR and STAT3 Pathway Hyper-Activation is Associated with evated Interleukin-6 Levels in Patients with Shwachman-Diamond Syndrome: Further Evidence of Lymphoid Lineage Impairment 115
AMIFOSTINE CAN REDUCE MUCOSAL DAMAGE AFTER HIGH-DOSE MELPHALANCONDITIONING FOR PERIPHERAL BLOOD PROGENITOR CELL AUTOTRANSPLANT: A RETROSPECTIVE STUDY. EFFECT OF AMIFOSTINE ON MUCOSITIS DURING AUTOLOGOUS PBPC TRANSPLANTATION 114
Mesenchymal stem cells of myelodysplastic syndromes show impaired hematopoietic support function and global DNA hypermethylation status 114
Telomere length, c-myc and mad-1 expression could represent prognosis markers of myelodysplastic syndrome 113
A Real Life Survey On Erythropoietin Alpha Treatment In a Cohort Of 1049 Low Risk MDS Patients: An Italian MDS Registry Study 113
Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study 113
Chronic Myelomonocytic Leukemia Diagnosis By Flow Cytometry: An Italian Center Experience 112
Assessment and monitoring of CMV infection in patients receiving a reduced-intensity conditioning allogeneic transplant: comparison of antigenaemia assay with quantitative PCR 112
CHANGES IN RPS14 EXPRESSION LEVELS DURING LENALIDOMIDE TREATMENT IN LOW- AND INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES WITH CHROMOSOME 5Q DELETION 111
DNA demethylating therapy reverts mesenchymal stromal cells derived from high risk myelodysplastic patients to a normal phenotype 111
Reporting Guidelines, Review of Methodological Standards, and Challenges Toward Harmonization in Bone Marrow Adiposity Research. Report of the Methodologies Working Group of the International Bone Marrow Adiposity Society 111
Ataluren improves myelopoiesis and neutrophil chemotaxis by restoring ribosome biogenesis and reducing p53 levels in Shwachman-Diamond syndrome cells 109
Hepatic, gastric and bone marrow AL amyloidosis that began with Budd-Chiari syndrome: a case report 109
Long duration of response to azacitidine in MDS. Multicenter retrospective study of 36 patients 108
Bone Marrow Immunological Changes During Treatment with Lenalidomide In Low and Intermediate-1 Risk Myelodysplastic Syndromes with Del(5Q) 108
AL amyloidosis: an overview on diagnosis, staging system, and treatment 107
Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment 106
VERY LOW TOXICITY AND GOOD QUALITY OF LIFE IN 48 ELDERLY PATIENTS AUTOTRANSPLANTED FOR HEMATOLOGICAL MALIGNANCIES: A SINGLE CENTER EXPERIENCE 106
Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS? 106
OVEREXPRESSION OF CDKN2B IS ASSOCIATED WITH REDUCED PROLIFERATIVE POTENTIAL IN MESENCHYMAL STEM CELL FROM HIGH-RISK MYELODYSPLASTIC SYNDROME 106
Totale 14.754
Salva come PNG Salva come JPEG
Categoria #
all - tutte 111.880
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 111.880
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.395 0 351 26 90 10 80 68 111 91 131 136 301
2022/20232.479 225 241 208 188 155 516 2 120 584 10 184 46
2023/20241.626 228 49 87 233 254 371 42 35 5 56 33 233
2024/20253.608 357 318 141 61 131 101 305 101 859 262 338 634
2025/20269.494 630 737 687 1.054 892 658 1.703 933 734 730 296 440
2026/2027939 505 434 0 0 0 0 0 0 0 0 0 0
Totale 24.971